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A hexanucleotide GGGGCC repeat expansion in the
noncoding region of the C9ORF72 gene is the most
common genetic abnormality in familial and sporadic
amyotrophic lateral sclerosis (ALS) and frontotempo-
ral dementia (FTD). The function of the C9ORF72
protein is unknown, as is the mechanism by which
the repeat expansion could cause disease. Induced
pluripotent stem cell (iPSC)-differentiated neurons
from C9ORF72 ALS patients revealed disease-spe-
cific (1) intranuclear GGGGCCexp RNA foci, (2) dysre-
gulated gene expression, (3) sequestration of
GGGGCCexp RNA binding protein ADARB2, and (4)
susceptibility to excitotoxicity. These pathological
and pathogenic characteristics were confirmed in
ALS brain andweremitigatedwith antisense oligonu-
cleotide (ASO) therapeutics to the C9ORF72 tran-
script or repeat expansion despite the presence of
repeat-associated non-ATG translation (RAN) prod-
ucts. These data indicate a toxic RNA gain-of-func-
tion mechanism as a cause of C9ORF72 ALS and
provide candidate antisense therapeutics and candi-
date human pharmacodynamic markers for therapy.
INTRODUCTION
A recently discovered hexanucleotide ‘‘GGGGCC’’ repeat’’
expansion in the noncoding region of the C9ORF72 gene has
been found in at least 8% of sporadic ALS (sALS) and FTD casesand more than 40% of familial ALS (FALS) and FTD cases
(DeJesus-Hernandez et al., 2011; Majounie et al., 2012; Renton
et al., 2011). Since the discovery of pathogenic repeat expan-
sions as a mechanism of disease in the 1990s, the list of neuro-
degenerative and neuromuscular disorders characterized by
unstable repeat expansions has grown to over 20 (Brouwer
et al., 2009; Pearson et al., 2005; Todd and Paulson, 2010).
Repeat expansions are classified as coding or noncoding
according to their gene location, and the disease-causing mech-
anisms include protein gain-of-function (Huntington’s disease,
HD), protein loss-of-function (FRAXA, FRDA), toxic RNA gain-
of-function (DM1&2) (for reviews, see Brouwer et al., 2009;
Gatchel and Zoghbi, 2005; Todd and Paulson, 2010), and non-
ATG-initiated translation (RAN) peptides (Mori et al., 2013b)
(Ash et al., 2013). The repeat expansion in DM1 alters activities
of RNA binding proteins (RBPs), including muscleblind-like 1
(MBLN1) (Fardaei et al., 2002; Grammatikakis et al., 2011; Miller
et al., 2000). MBLN1 is sequestered in the nucleus by the repeat-
containing RNA resulting in the formation of a pathogenic
protein:RNA complex that, when visualized by RNA fluorescent
in situ hybridization, form an intranuclear RNA foci, which leads
to a loss of protein activity and reduces alternative splicing of
other genes (Kanadia et al., 2003, 2006). Notably, intranuclear
GGGGCC RNA foci have also been found in the motor cortex
and spinal cord of C9ORF72 ALS/FTD patients (DeJesus-
Hernandez et al., 2011), suggesting that, like myotonic dystro-
phy, RNA toxicity plays a role in C9ORF72 neurodegeneration.
To understand the pathogenesis of the C9ORF72 expansion
and to develop possible therapeutics, we generated a collec-
tion of C9ORF72 ALS induced pluripotent stem cells (iPSCs)
and differentiated them into neurons (iPSNs). Using this
model system, we discovered intranuclear C9ORF72 repeat-
containing RNA foci in all tested humanC9ORF72 iPSN cell lines.Neuron 80, 415–428, October 16, 2013 ª2013 Elsevier Inc. 415
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Figure 1. C9ORF72ALS iPSNs Exhibit GGGGCCexpRepeat Allele and
Reduced C9ORF72
(A) Southern blot of C9ORF72 ALS fibroblasts and subsequent iPSCs for lines
used in this study. All C9ORF72 lines contained normal length allele (Wt) and an
expanded ‘‘GGGGCC’’ repeat allele (E) that is maintained during differentiation
to iPSN (N) or astrocytes (A).
(B) Repeat length of iPSCs was maintained over several iPSC cell passage
numbers (ranging from p13 to p59).
(C) Schematic of the C9ORF72 gene, location of the repeat sequence (yellow),
validated RNA variants, and location of the nanostring probesets. For detec-
tion of nanostring probe, each individual probe (red) must bind in tandem for
detection (green). Probes to C9ORF72 V1 will detect pre-mRNA and mRNA;
probes to V2 and V3 will only detect C9ORF72 mRNA.
(D) C9ORF72 ALS iPSNs andCNS tissue exhibit reducedC9ORF72RNA levels
(n for C9ORF72 versus Control: n = (fibroblast, Fibro) 5 versus 5; (iPSN) 3
versus 3; (cerebellum, Cereb) 4 versus 6; (motor cortex, Mt Ctx) 10 versus 6;
(cervical spinal cord, CSC) 4 versus 6).
(E) Non-C9ORF72 ALS patients do not show attenuated levels of
C9ORF72 RNA.
(*p < 0.05; ***p < 0.001). See also Figures S1 and S2; Tables S1, S2, and S3.
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C9ORF72 RNA Toxicity Rescued by AntisenseFurthermore, we identified several protein binding partners for
the expanded GGGGCC RNA (GGGGCCexp) and confirmed
that the RNA binding protein ADARB2 interacts with nuclear
GGGGCC RNA foci. In addition, we discovered aberrantly
expressed genes in C9ORF72 cells and determined that
C9ORF72 ALS iPSNs are highly susceptible to glutamate-medi-
ated excitotoxicity. To validate the use of this iPSC model, we
confirmed these expanded C9ORF72-related phenotypes in
postmortem human ALS CNS tissue. Finally, iPSN treatment
with novel antisense oligonucleotides (ASOs) that target the
GGGGCCexp RNA sequence but do not lower C9ORF72 RNA
levels mitigate all toxic phenotypes. Although RAN proteins,
translated from the mutant GGGGCC expansion, are present in
these iPSNs, they do not appear to contribute to the observed
acute neurotoxicity. Taken together, these data support the
theory that the generation of toxic RNA plays a major role in
C9ORF72 ALS and that specifically targeted antisense can
effectively prevent neurotoxicity. These iPSC studies, through
the development of pathological readouts, support the develop-
ment of a novel antisense therapy to treat neurodegeneration
due to the C9ORF72 repeat expansion.
RESULTS
C9ORF72 iPSCs Exhibit the GGGGCC Repeat Expansion
and Have Reduced C9ORF72 RNA Levels
iPSC models are useful for studying human disease pathogen-
esis and could serve as a powerful human and allele-specific
tool to evaluate therapeutics. To study the pathology of the
C9ORF72 repeat expansion, we isolated fibroblasts from unre-
lated C9ORF72 ALS patients whose repeat expansion was
confirmed by repeat-primed PCR (Renton et al., 2011) and
Southern blot analysis (Figures 1A and 1B; for demographic in-
formation on all cell lines see Table S1 available online), reprog-
rammed them to TRA-1-60+ iPSCs (Dimos et al., 2008), and
differentiated them to Tuj-1+ iPS-derived neurons (Figure S1A).
iPSC lines were generated from fibroblasts reprogramed using
Sox2, Oct4, Klf4, and c-Myc encoding vectors (data not shown).
All iPSC lines were validated via strict quality control profiling
including expression of pluripotency markers as well as normal
karyotyping (data not shown). The iPSN cultures are composed
of a heterogeneous neuronal cell population, of which about
30%–40% stained positive for motor neuron marker HB9 (Fig-
ure S1B). It is widely known that not only motor neurons, but
also cortical neurons, interneurons, and glia are pathologically
injured in ALS (Morrison et al., 1998; Kang et al., 2010; Reis
et al., 2011), which is why studies were carried out using a mixed
neuronal cell population. Southern blot analysis revealed that the
GGGGCC expansion is maintained in all lines after reprogram-
ming and differentiation from fibroblast to iPSC neurons or astro-
glia (Figure 1A) with little or minor changes in expansion size,
which is likely to be reflected by clonal selection of fibroblasts.
No expansion size instability was observed after increasing cell
passage numbers in vitro (>50; Figure 1B).
Earlier studies have shown that ALS and FTD patients exhibit
decreased C9ORF72 RNA levels in patient tissue as measured
by real-time PCR (Ciura et al., 2013; DeJesus-Hernandez et al.,
2011; Gijselinck et al., 2012). Therefore, to determine whether416 Neuron 80, 415–428, October 16, 2013 ª2013 Elsevier Inc.
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C9ORF72 RNA Toxicity Rescued by Antisensepatient fibroblasts and iPSNs exhibit similar in vivo C9ORF72
RNA variant expression patterns, we quantified C9ORF72 RNA
levels in C9ORF72 ALS fibroblasts, in iPSNs, and in human
CNS regions from multiple unrelated patients (Table S2) using
the highly sensitive, probe-based nanostring RNA detection sys-
tem (probe sequences in Table S3). This method is ideal for
screening human tissue due to the lack of any nucleotide ampli-
fication step. There are three validated mRNA products tran-
scribed from the C9ORF72 gene, C9ORF72 variant 1, 2, and 3
(NM_145005.5, NM_018325.3, and NM_001256054.1, respec-
tively) with variant 1 and 3 containing open reading frames
(ORFs) upstream of the expanded GGGGCC repeat. To detect
the levels of each C9ORF72 RNA variant and to compare each
variant between samples we generated two 50-mer nanostring
probes for each transcript that target one of the C9ORF72 vari-
ants. In order for the RNA variant to be detected, each 50-mer
probe must bind in tandem (schematic shown in Figure 1C).
Similar to previous studies, C9ORF72 V1 and V2 RNA levels
were attenuated by 50% in C9ORF72 ALS CNS tissue (n =
5–10) compared to healthy controls (n = 4–10) (Figure 1D). Inter-
estingly, iPSNs (n = 3) exhibited a similar expression pattern with
an approximate 50% reduction in C9ORF72 V1 and V2 RNA
levels, while patient fibroblasts showed low C9ORF72 expres-
sion with no obvious differences between the control and
C9ORF72 ALS lines (although slight differences may be
confounded by the lower absolute RNA counts) (Figure 1D). In
human CNS tissue, the highest quantity of C9ORF72 RNA is
found in the cerebellum and cervical spinal cord. Importantly,
in non-C9ORF72 ALS tissue, C9ORF72 RNA levels were compa-
rable to healthy control tissue (Figure 1E). While we tested for the
presence of C9ORF72 V3 RNA using probes targeting the
spliced mRNA sequence (Figure 1C), it could only be detected
slightly above background in iPSNs and cervical spinal cord tis-
sue with no obvious expression differences between control and
C9ORF72 ALS cells/tissue (Figure S2A). However, probes tar-
geting C9ORF72 intron 7, which detect V2 and V3 pre-mRNA,
exhibited a statistically significant reduction of this RNA
sequence in C9ORF72 ALS compared to control and non-
C9ORF72 ALS tissue, suggesting that the prespliced levels of
C9ORF72 V2 and V3 RNA are also reduced in endogenous tissue
(Figure S2B). Whether these changes in RNA correlate with
endogenous protein are uncertain, as current antibodies to
C9ORF72 protein are not suitable for specific quantification
(data not shown). While the function of the C9ORF72 protein is
unknown, a recent study in zebrafish has shown that C9ORF72
deficiency via ASO knockdown results in locomotor deficits
and abnormal growth and morphology of motor axons (Ciura
et al., 2013). Further studies are required to determine whether
a C9ORF72 deficit in human ALS/FTD contributes to the disease
phenotype.
C9ORF72 ALS iPSCs Exhibit Toxic RNA Foci
We detected intranuclear GGGGCC RNA foci in C9ORF72 ALS
patient tissue, iPSNs, and fibroblasts by RNA fluorescent
in situ hybridization (RNA FISH), similar to previous reports of
postmortem CNS tissue (DeJesus-Hernandez et al., 2011),
employing fluorescently labeled locked nucleic acid (LNA) oligo-
nucleotide probes targeting the expanded repeat (Figures 2Aand S3A). This pathology was not present in non-C9ORF72 con-
trol cells or C9ORF72 cells labeled with scrambled FISH probes
(Figures 2B and S3A). Specifically, we observed that, across five
C9ORF72 fibroblast and four C9ORF72 iPSN lines, approxi-
mately 25% and 35% of cells contained intranuclear GGGGCC
RNA foci, respectively (Figures 2B, 2C, and S3A). When
compared to fibroblasts, the higher percentage of RNA foci
containing cells and the higher number of foci/cell in the iPSN
might be explained by the higher C9ORF72 expression levels
(Figures 1D and 2C). It is important to note that the high G:C
content of the C9ORF72 expanded RNA poses technical chal-
lenges for RNA FISH probe targeting; as such, it is possible
that we are only visualizing a fraction of the actual RNA foci pre-
sent in the cultures. Nevertheless, this same approach has suc-
cessfully identified nuclear GC repeats in fragile X diseased
tissue (Sellier et al., 2013). Specificity of the FISH probes was
confirmed by treatment of cells with RNase A and DNase I, which
reduced andmaintained the RNA foci respectively, strongly sug-
gesting that these intranuclear inclusions are comprised of
‘‘GGGGCC’’ RNA and not DNA (Figures 2B and 2C).
The C9ORF72mutation resembles the DM2mutation, which is
caused by a long CTTG tract in the first intron of the ZNF9 gene
that generates a toxic CCUGexp RNA (Lee and Cooper, 2009;
Udd and Krahe, 2012). In DM2, the intranuclear RNA foci are
comprised of the expanded RNA repeat and not the surrounding
intronic or exonic regions (Margolis et al., 2006). Therefore, utiliz-
ing dual RNA FISH methodologies, we investigated the compo-
sition of the C9ORF72 GGGGCCRNA foci in the iPSNs (Margolis
et al., 2006). To achieve this, we probed control and C9ORF72
iPSNs with a 50digoxigenin-labeled LNA probe to the GGGGCC
repeat and a 50FAM-labeled LNA probe to sequences upstream
(probe 1) or downstream (probes 2–5) of the expanded repeat
targeting either C9ORF72 exons or introns (Figure 2D). This
approach allowed us to determine whether the full C9ORF72
transcript is sequestered into nuclear GGGGCC RNA foci. We
did not observe nuclear foci when visualizing FISH probes that
target these sequences. Moreover, the staining pattern of
50FAM-labeled LNA probes in control non-C9ORF72 iPSNs
was similar to C9ORF72 iPSN staining (Figure 2E, upper panel)
and differed from the GGGGCC targeting probes in the
C9ORF72 iPSN (Figure 2E, lower panel), suggesting that
C9ORF72 RNA exonic or intronic sequences upstream or down-
stream of the repeat are not primary components of the nuclear
RNA foci (Figure 2E).
C9ORF72 ALS iPSCs Exhibit RAN Translation Pathology
The percentage of cells with cytoplasmic foci in C9ORF72 cells
was significantly higher than in control fibroblasts and iPSNs,
as was the number of cytoplasmic GGGGCC foci per cell (Fig-
ures 3A, 3B, and S3B). Moreover, similar cytoplasmic foci could
be found in C9ORF72 ALS postmortemmotor cortex (Figure 3C).
The presence of these cytoplasmic RNA foci suggested that the
expanded GGGGCC RNA may undergo non-ATG-initiated
translation (RAN) (Ash et al., 2013; Mori et al., 2013b) resulting
in the accumulation of high-molecular-weight cytoplasmic
dipeptide protein products, namely, poly-(Gly-Ala), poly-(Gly-
Pro), and poly-(Gly-Arg) (Ash et al., 2013), a process similar to
microsatellite RNA products in DM1 and spinocerebellar ataxiaNeuron 80, 415–428, October 16, 2013 ª2013 Elsevier Inc. 417
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Figure 2. C9ORF72 ALS iPSN Exhibit Patho-
logical Nuclear GGGGCCexp RNA Foci
(A) Single optical plane (0.3 mm) of C9ORF72 iPS-
differentiated neurons processed for GGGGCC
RNA FISH exhibit clear intranuclear foci (left)
similar to those found in C9ORF72 ALS motor
cortex (right).
(B and C) GGGGCC probe is specific to C9ORF72
RNA foci and foci are RNase A sensitive (n = 30
fields of view).
(D) Schematic of RNA FISH probe location relative
to C9ORF72 RNA variants.
(E) Probes to exonic and intronic regions upstream
and downstream of the repeat (red) do not form
nuclear foci, do not consistently overlap with
GGGGCC RNA foci (green), and exhibit similar
localization in control and C9ORF72 ALS iPSN
lines. Dotted line outlines cell nucleus.
Data in (C) indicate mean ± SEM (p < 0.001). Scale
bar = 2 mm for (A), 20 mm for (B), and 5 mm for (E).
See also Figure S3A.
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C9ORF72 RNA Toxicity Rescued by Antisensetype 8 (SCA8) (Zu et al., 2011). Utilizing an antibody that was
raised against the poly-(Gly-Ala), poly-(Gly-Pro), and poly-(Gly-
Arg) RAN protein products but preferentially detects the poly-
(Gly-Pro) RAN product in C9ORF72 human tissue (Ash et al.,
2013), we tested for the presence of cytoplasmic RAN protein in
C9ORF72 iPSNs. Immunofluorescent staining of the C9ORF72
iPSNs revealed cytoplasmic poly-(Gly-Pro) RAN protein in
C9ORF72 ALS iPSNs with only light background staining in
some non-ALS control iPSNs (Figures 3D and 3E) (Ash et al.,
2013), thus matching the pathology of C9ORF72 postmortem
patient CNS tissue.
RNA Binding Protein ADARB2 Interacts with
GGGGCC RNA
In noncoding repeat expansion disorders, pathogenesis may be
due to the accumulation of expanded repeat-containing RNA
transcripts that sequester RNA binding proteins (RBPs) (Eche-
verria and Cooper, 2012). The presence of intranuclear RNA
foci in C9ORF72 ALS cells suggests that the expanded
GGGGCC RNA might also sequester RBPs. The identification418 Neuron 80, 415–428, October 16, 2013 ª2013 Elsevier Inc.of such GGGGCCexp RBPs may prove
critical for understanding the mecha-
nisms of C9ORF72-mediated neuro-
degeneration and could further be
important for the identification of candi-
date therapies.
Previously, proteome arrays have been
successfully utilized to identify protein-
binding partners for long noncoding
RNAs (Rapicavoli et al., 2011). We utilized
this unbiased, in vitro high-throughput
methodology to investigate potential
GGGGCC RNA interactors. A 50Cy5-
labeled GGGGCC 3 6.5 RNA was synthe-
sized and hybridized to a proteome
array containing nearly two-thirds of the
annotated human proteome as yeast-expressed, full-length ORFs with N-terminal GST-His3 6 fusion
proteins (a total of 16,368 full-length human proteins repeated
2–3 times per chip) (Jeong et al., 2012). A 50Cy5-labeled scram-
bled RNA of the same G:C content as the 50Cy5-labeled
GGGGCC 3 6.5 RNA was used as a negative control. For each
RNA sequence, three proteome arrays were hybridized in
parallel as technical replicates. Using this method, we identified
19 ORFs that consistently exhibited high affinity for the
GGGGCC 3 6.5 RNA as compared to the scrambled RNA deter-
mined via the DZ-score (GGGGCC 3 6.5 RNA Z score – G:C
scrambled RNA Z score) (Table S4; for a complete list of all bind-
ing proteins and their respective Z score for each RNA see Table
S5). Notably, the GGGGCC RNA has been shown to form a
G-quadruplex structure (Fratta et al., 2012; Reddy et al., 2013)
and our G:C scrambled negative probe is predicted to form the
same structure. Therefore, we very conservatively screened for
binding partners to the repeat sequence, excluding any hits
that would nonspecifically bind the G-quadruplex structure. In
addition, the proteome array will identify protein interactors inde-
pendent of their respective cellular abundance unlike standard
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Figure 3. C9RF72 ALS Cells Show Cyto-
plasmic RAN Translation Peptides
(A) C9ORF72 iPSN cells contain cytoplasmic
GGGGCC RNA foci, while control iPSNs do not.
(B) Quantification of cytoplasmic RNA foci reveals
that cytoplasmic foci are RNase A sensitive.
(C) Single-optical plane (0.3 mm) image of
C9ORF72 ALS motor cortex also shows cyto-
plasmic GGGGCC RNA foci similar to iPSNs.
(D) RAN protein shown by IF using C9RANT anti-
body that preferentially detects the poly-(Gly-Pro)
RAN product in C9ORF72 iPSNs but not control
iPSNs.
***p < 0.001. Scale bar = 5 mm for (A), (D), and (E),
right panels; 1 mm for (C), and 20 mm for (D) and (E),
left panels. See also Figure S3B.
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C9ORF72 RNA Toxicity Rescued by AntisenseRNA affinity assays from cell lysates and protein identification via
mass spectrometry. From the 19 GGGGCC 3 6.5 interactor can-
didates, we chose ADARB2, a known RBP, to study its role in
C9ORF72 pathology in greater detail.
Simultaneous RNA FISH and RBP immunofluorescence (RNA
FISH-IF) studies in C9ORF72 iPSNs revealed that ADARB2 pro-
tein colocalizes with the nuclear GGGGCC RNA foci (Figure 4A),
with unchanged levels of mRNA (Figure S4A). In addition,
RBP:RNA coimmunoprecipitation (RNA co-IP) studies allowed
us to isolate C9ORF72 RNA from the RNA co-IP using primers
to exon 1a and the intronic region 50 of the GGGGCC expanded
repeat (Figures 4B and S4B), indicating that ADARB2 interacts
with endogenous C9ORF72 RNA in living cells. Finally, we per-
formed an electrophoretic gel shift assay (EMSA) with recombi-
nant ADARB2 purified from E. coli (Figures S4C and S4D).
Titrating ADARB2 clearly shows depletion of free RNA and shift
to slower mobility or a well shift, the latter of which is presumably
due to multimerization of the protein:RNA complexes (Figures
S4D and S4E). Taken together, these data indicate that both bio-
chemically and in living cells, ADARB2 protein interacts with
C9ORF72 RNA and has a high binding affinity for the GGGGCC
repeat RNA sequence, which could be useful as a readout to
monitor C9ORF72-specific drug efficacy.
To determine whether these in vitro observations are recapit-
ulated in vivo, we examined the colocalization of ADARB2 pro-
tein to GGGGCC RNA foci in human postmortem C9ORF72
patient tissue. RNA FISH-IF confirmed that ADARB2 colocalizes
with GGGGCC RNA foci in motor cortex of C9ORF72 ALS
patients, while there is no nuclear accumulation or colocalization
in non-C9 ALS tissue (Figure 4C).
Since ADARB2 appears to interact with endogenous
C9ORF72 RNA through the GGGGCC repeat sequence, we
examined whether ADARB2 is required for RNA foci formation,
similar to the MBNL1 requirement for foci formation in DM1Neuron 80, 415–428and DM2 (Lee and Cooper, 2009; Udd
and Krahe, 2012). To test this, we treated
iPSNs with siRNA against ADARB2 and
performed RNA FISH for the nuclear
GGGGCC RNA foci. siRNA-mediated
knockdown of ADARB2 resulted in a sta-
tistically significant 48.99% reduction inthe number of iPSNs with RNA foci (Figures 4D and 4E). These
studies suggest that an interaction between ADARB2 and the
C9ORF72 RNA expansion plays a role in the formation or main-
tenance of the RNA foci in vitro, supporting the hypothesis that
interactions of RBPs with the GGGGCC repeat may play a role
in GGGGCCexp RNA toxicity. Moreover, we observed that
ADARB2 appeared to statistically accumulate in the nucleus of
C9ORF72 iPSN by immunostaining (Figures S5A and S5B) and
this was recapitulated in C9ORF72 ALS postmortem tissue (Fig-
ures S5C and S5D).
Recent studies performing in vitro pull down assays have
implicated other RBPs as potential GGGGCCexp RNA binding
partners, including hnRNPA3 (Mori et al., 2013a) and Pur a (Xu
et al., 2013). While these RBPs were not included on the prote-
ome arrays used in this study, we performed immunohistochem-
ical analyses of multiple RBPS, including P62, hnRNPA1,
hnRNPA1B2, FUS, P62, and Pur a (Figure S5E). We also
included TDP43, a well-characterized RNA binding protein in
ALS pathology and pathophysiology. Macroscopic immuno-
staining suggests that unlike for ADARB2, none of the other
RBPs formed distinct nuclear aggregates in the C9ORF72
iPSC neuron cultures when compared to control iPSNs.
Transcriptome of C9ORF72 Cells and Tissue
Sequestration of RBPs and the presence of nuclear foci suggest
that the expansion mutation may alter the cellular transcriptome,
which could provide yet another readout for therapeutic inter-
vention. Using five C9ORF72 ALS fibroblast lines, we identified
unique gene expressions changes (p < 0.05) when compared
to healthy controls, and accounted for significantly altered
genes from SOD1mut fibroblasts (Figures S6A and S6B; Tables
S6 and S7). Similarly, we found that, using four iPSN lines a
unique population of genes were dysregulated as compared
to control, again subtracting the aberrantly expressing genes, October 16, 2013 ª2013 Elsevier Inc. 419
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Figure 4. ADARB2 Protein Binds to the GGGGCCexp of C9ORF72 RNA
(A) Single optical plane (0.34 mm) colocalization of GGGGCC RNA foci with ADARB2 protein signal in C9ORF72 iPSN.
(B) ADARB2 co-IP with bound RNA was performed; RNA was isolated from ADARB2 protein co-IP in control and C9ORF72 iPSNs. RT-PCR of the co-IP RNA
using two primer sets (red) upstreamof the C9ORF72GGGGCC repeat (schematic, blue =UTR) indicates that ADARB2binds to theC9ORF72RNA in both control
and C9ORF72 iPSNs. Amplification of DMPK and GAPDH were used to test for immunoprecipitation specificity (lower panel).
(C) Single optical plane (0.3 mm) image demonstrating colocalization of GGGGCC RNA foci and ADARB2 in C9ORF72 patient postmortemmotor cortex tissue,
layers 3–5.
(D and E) siRNA knockdown of ADARB2 results in a significant reduction in the percent of iPSNs with nuclear RNA foci (arrows). Data in (E) indicate mean ± SEM
(***p < 0.001).
Scale = 2 mm for (A) and (C), and 15 mm for (D). See also Figure S4 and S5; Tables S4 and S5.
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C9ORF72 RNA Toxicity Rescued by Antisensefrom SOD D90A iPSN lines (Figures 5A and S6C; Table S8). iPSNs
that carry a SOD1D90A mutation exhibited a large number of dys-
regulated genes when compared to control cells, although a
subset of expression abnormalities were common between
C9ORF72 and SOD1D90A iPSNs (Figures 5A and S6C; Tables
S9 and S10). Taken together, these data indicate that the
C9ORF72 transcriptome is different from the SOD1mut transcrip-
tome in both fibroblasts and iPSNs. This can be visualized when
comparing the expression levels of statistically significant genes
in C9ORF72 iPSNs to that of SOD1D90A iPSNs (Figure S6D).
To evaluate whether cultured iPSNs recapitulate the C9ORF72
ALS human brain transcriptome andmight therefore be used ulti-
mately to evaluate future therapeutics, we next examined any
commonalities between C9ORF72 iPS-derived neurons and
postmortemmotor cortex (n = 3) (Figure 5B).We identified a large
number of aberrantly expressedgenes (p<0.05) inC9ORF72ALS
motor cortex (compared to control) of which a subset overlapped
with genes aberrantly expressed in C9ORF72 iPSNs, including
those expressed concordantly (Figures 5B and S6E–S6F and
Tables S11 and S12). When comparing C9ORF72 fibroblasts to
C9ORF72 iPSN and motor cortex, fewer genes were found to
be common suggesting that these cell types are not very similar
(FiguresS6EandS6FandTablesS13 andS14). Only a population
of altered genes is shared between the postmortem C9ORF72
human motor cortex and the C9ORF72 iPSNs, most likely due
to the cellular heterogeneity of the human motor cortex as com-
pared to a neuron-enriched iPSN culture system. Interestingly,420 Neuron 80, 415–428, October 16, 2013 ª2013 Elsevier Inc.all C9ORF72 cell and tissue gene arrays consistently showed a
larger number of downregulated genes than upregulated genes,
which was not observed in the SOD1mut samples (Table S15).
With the goal of identifying genes that might be utilized as ther-
apeutic biomarkers, we selected genes that exhibited altered
expression in C9ORF72 iPSNs, fibroblasts, or human motor cor-
tex via exon microarray. We specifically selected genes coding
for proteins that are expressed in the CNS and predicted to be
secreted. In choosing these, we hoped that their levels could
be quantified in patient cerebrospinal fluid (CSF) as this would
allow for monitoring during antisense treatment, similar to what
we recently reported for human SOD1 antisense therapy (Reddy
et al., 2013). We selected 26 target genes (Table S16) and tested
their expression in C9ORF72 autopsied CNS tissue against non-
ALS control tissue using nanostring gene expression methodol-
ogies. Sixteen of the target genes tested were also aberrantly
expressed in C9ORF72 ALS patient tissue (Figures 5C, S7A,
and S7B), of which seven showed the same direction of dysregu-
lation (up or down) when compared to iPSNs (Figure 5D). These
genes could be potential candidates for the future development
of a pharmacodynamic biomarker to monitor C9ORF72 therapy
in human CSF and/or blood.
C9ORF72 ALS iPSC Neurons Are Highly Susceptible to
Glutamate-Mediated Excitotoxicity
Glutamate toxicity has been shown to play a major role in ALS as
sporadic ALS and C9ORF72 patients exhibit a loss of astroglial
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Figure 5. C9ORF72 ALS-Specific Gene
Expression
(A) Venn diagrams comparing the differentially
expressed, statistically significant genes in
C9ORF72 iPSNs versus control iPSNs and
SOD1D90A iPSN versus control iPSNs indicate vast
differences in global gene expression. Red in-
dicates upregulated genes; blue indicates down-
regulated genes.
(B) Gene expression comparison of common, sta-
tistically significant gene expression in C9ORF72
iPSNs versus control (negating any genes signifi-
cant in SOD1D90A versus control iPSNs) and
C9ORF72 human motor cortex tissue (versus
healthy control motor cortex). p < 0.05.
(C and D) Targeted gene expression analysis of
aberrantly expressed secreted genes, chosen by
microarray results, in human motor cortex and
spinal cord revealed dysregulation of seven genes
that were also found to be similarly dysregulated in
C9ORF72 iPSNs (versus control). Data in (C) and
(D) indicate mean ± SEM.
*p < 0.05; **p < 0.01; ***p < 0.001. See also Fig-
ure S6 and S7; Tables S6–S16.
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C9ORF72 RNA Toxicity Rescued by Antisenseglutamate transporter 1 (GLT-1/EAAT2), which buffers synaptic
glutamate thus preventing excitotoxicity (Lin et al., 1998; Roth-
stein et al., 1995; Renton et al., 2011). Notably, C9ORF72 iPSNs
express glutamate receptors (GluR2), NMDA receptors (NR2B),
and postsynaptic marker protein postsynaptic density protein-
95 (PSD95), comparable to control iPSNs, thus suggesting that
these cells form functional synapses and are capable of re-
sponding to glutamate-induced excitotoxicity (Figure 6A).
To determine whether the C9ORF72 mutation leads to an
altered physiology in iPSC neurons, we explored sensitivity to
glutamate excitotoxicity. Glutamate treatment resulted in a
dose- and time-dependent increase of cell death in control
and C9ORF72 iPSN cultures as determined by cellular propi-
dium iodide (PI) uptake (Sattler et al., 1997; Sattler et al.,
1999) (Figures 6B–6D and S8). Notably, C9ORF72 ALS iPSNs
are almost 100-fold more sensitive to glutamate treatment, as
toxicity at 3 mM glutamate in healthy control iPSNs was compa-
rable to death at 100 mM glutamate in C9ORF72 iPSNs (Figures
6B and S8). Glutamate-induced cell death was blocked by
inhibitors of glutamate receptors and calcium channels (MK-
801, 10 mM; CNQX, 10 mM; nimodipine, 2 mM; Sattler et al.,
1999), confirming that C9ORF72 iPSN cell death was gluta-
mate-receptor dependent (Figure 6E).
To test whether the sequestration of ADARB2 plays a role
in the observed glutamate susceptibility, we knocked down
ADARB2 levels in healthy control iPSNs via siRNA treatmentNeuron 80, 415–428,(Figure 6F) and investigated their suscep-
tibility to glutamate-mediated cell death.
Interestingly, a loss of about 50% of
ADARB2 RNA significantly enhances
control iPSC neurons’ susceptibility to
glutamate (30 mM at 4 hr) to levels similar
to those observed in C9ORF72 iPSNs
(Figures 6F and 6G). This suggests thata partial loss of ADARB2 via sequestration to GGGGCC RNA
might play a role in C9ORF72-mediated RNA toxicity.
Antisense Oligonucleotides Rescue C9ORF72 Toxic
Phenotype
If an RNA-dominant pathogenic mechanism exists for C9ORF72
ALS, it could be a candidate for antisense oligonucleotide thera-
peutics. For example, in DM1, (CAG)7 ASOs have successfully
been utilized to reverse expanded RNA toxicity in vitro as well
as to normalize in vivo aberrant RNA splicing in transgenic
models by reducing toxic (CUG)n RNA (Mulders et al., 2009).
Similarly, (CAG)25 ASOs (PMOs), which bind, but not degrade,
the (CUG)n RNA, block MBNL1 interaction with the toxic RNA
and rescue the animal model disease phenotype (Wheeler
et al., 2009). In the DM1 mouse nuclear-retained RNA species
are highly susceptible to ASOs that work through the RNase H
mechanism (Osborne et al., 2009; Wheeler et al., 2012), resulting
in loss of RNA foci and reversal of myotonia and spliceopathies
(Wheeler et al., 2012). Based upon these findings we screened
over 250 chimeric MOE/DNA RNase H active ASOs (Gapmers)
(Figure S9A) designed to bind to multiple regions of the
C9ORF72 transcript as well as to the GGGGCCexp RNA, a selec-
tion of which are included in this study (Figures 7A and S9B). In
addition, we studied an ASO that binds the GGGGCCexp RNA
repeat to block any RBP interaction but does not degrade the
transcript (Figure S9B).October 16, 2013 ª2013 Elsevier Inc. 421
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Figure 6. C9ORF72 ALS iPSC Neurons Are
Highly Susceptible to Glutamate Toxicity
(A) Immunofluorescent staining of control and
C9ORF72 iPSN cultures show expression of
glutamate receptors GluR2, NR2B, and post-
synaptic density protein PSD95 at comparable
levels as determined by qualitative analysis. Box
indicates region of high magnification seen
below each image (scale = 10 mm [top] and 2.5 mm
[bottom]).
(B) Dose response curve of control and C9ORF72
iPSC neurons revealed that C9ORF72 iPSNs are
highly susceptible to glutamate excitotoxicity at
1, 3, 10, and 30 mM concentrations after 8 hr of
treatment by popidium iodide staining.
(C) Glutamate-induced excitotoxicity of C9ORF72
iPSNs shows statistically significant cell death
after 4 hr of 30 mM glutamate treatment when
compared to control iPSNs.
(D) Representative image of propidium iodide
staining of control and C9ORF72 ALS iPSN after
4 hr of 0 and 30 mM glutamate treatment; note the
increased prodium iodide signal in the C9ORF72
iPSNs as compared to the control iPSNs.
(E) Blocking glutamate receptors prevents gluta-
mate-induced C9ORF72 iPSN cell death (4 hr,
30 mM glutamate).
(F and G) Knockdown of ADARB2 via siRNA
treatment resulted in a statistically significant
increased susceptibility to glutamate-induced ex-
citotoxicity in control non-C9ORF72 iPSNs at 4 hr,
30 mM glutamate treatment.
Data in (B), (C), (E), and (G) indicate mean ± SEM
(*p < 0.05; ***p < 0.001). See also Figure S8.
Neuron
C9ORF72 RNA Toxicity Rescued by AntisenseWe tested the efficacy of ASOs using C9ORF72 ALS patient
fibroblast lines as well as three patient iPSN lines. Our results
indicate that ASOs targeting the GGGGCCexp (ASO: A–C) do
not reduce C9ORF72 V1 or V2 RNA levels in fibroblasts or iPSNs
regardless of their intended effect (block or RNase H activation)
(Figures 7A, 7B, and S9C). In contrast, gapmer ASOs targeting
the intronic region downstream of the repeat or exon 2 effectively
reduced C9ORF72 V1 and V2 RNA levels in C9ORF72 patient
fibroblasts and iPSNs when compared to cells treated with a
non-targeting ASO (Figures 7B and S9C).
RNase H-mediated C9ORF72 knockdown significantly
reduced both the percentage of cells that contain GGGGCCexp
RNA foci (Figures 7C and S9D) and the number of foci per cell
in both fibroblasts and iPSN cultures regardless of its target loca-
tion (expansion, intronic region, or coding sequence) or effect on
C9ORF72 RNA levels (Figures 7C and S9D–S9F). This suggests
that ASO protection against RNA toxicity can be obtained
without reducing C9ORF72 RNA levels, which could be impor-
tant for future therapeutic development.
If ADARB2 colocalization with RNA foci (Figures 4A and 4C) is
due to protein:GGGGCCexp RNA interaction, then ASOs that
reduce RNA foci might also attenuate the observed ADARB2
nuclear accumulation observed in C9ORF72 ALS iPSN and
motor cortex. Indeed, all ASOs tested reduced the nuclear
ADARB2 protein signals in C9ORF72 iPSNs as determined by
immunostaining (Figures S9G and S9H).422 Neuron 80, 415–428, October 16, 2013 ª2013 Elsevier Inc.ASO treatment also normalized the dysregulated gene expres-
sion of our candidate biomarker genes NEDD4L, FAM3C,
CHRDL1, SEPP1, and SERPINE2 in C9ORF72 iPSNs (Figure 7D)
independent of the ASO target region, hence independent of
C9ORF72 RNA knockdown. Thus, these genes could indeed
serve as potential biomarkers to monitor ASO therapy efficacy.
Importantly, genes that were not altered between control and
C9ORF72 iPSNs did not change when treated with ASOs, sug-
gesting that ASO treatment does not have untoward effects on
general gene transcription (Figure S9I).
Finally, we tested whether ASO treatment might rescue
the susceptibility to the glutamate excitotoxicity observed in
C9ORF72 iPSNs. iPSNs treated with ASOs targeting the repeat
sequence or targeting C9ORF72 exon 2 were exposed to
30 mM glutamate for 4 hr and monitored for cell death. ASOs tar-
geting the repeat, without altering C9ORF72 RNA levels, signifi-
cantly rescued the glutamate toxicity phenotype by up to 30%.
ASOs targeting exon 2, which reduced C9ORF72 mRNA levels,
still significantly protected the iPSN by 16% (Figures 7E and
S9J). This suggests that the loss of C9ORF72 mRNA and subse-
quent loss of C9ORF72 protein do not play a role in the observed
vulnerability to glutamate, but instead implies that RNA toxicity
causes C9ORF72 cells to be highly sensitive to excitotoxicity.
This is further supported by the fact that RAN products were still
detected in the C9ORF72 iPSNs after ASO treatment, through
either immunocytochemistry or protein blotting, despite a rescue
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Figure 7. Antisense Oligonucleotides
Rescue RNA Toxicity Observed in C9ORF72
iPSC Neurons
(A) Map of the C9ORF72 gene indicating the ASOs
utilized in this study. ASO B is endonuclease
resistant and designed to block the repeat while
the remaining are gapmers, which mediate RNA
degradation through an RNase H-based mecha-
nism. Dotted line indicates end of V1 Exon 1A
sequence.
(B) ASOs that target the repeat sequence do not
statistically alter C9ORF72RNA levels in C9ORF72
iPSNs, while ASOs downstream of the repeat
significantly reduce the levels of C9ORF72 vari-
ants 1 and 2.
(C) All ASOs significantly reduced the number
of nuclear GGGGCC RNA foci observed in
C9ORF72 iPSNs to levels comparable to the
RNase A-treated cells while treatment with a
nontargeting scrambled probe did not affect the
percent of cells with nuclear foci.
(D) ASO treatment was able to rescue the aberrant
expression of NEDD4IL, FAM3C, CHRDL1, SEPP1,
and SERPINE2 in a statistically significant manner.
(E) ASO B, C, and E rescued the increased
susceptibility of C9ORF72 iPSNs to glutamate
exposure (30 mM glutamate, 5 hr).
(F) ASO treatment for 3 days does not dramatically
reduce the levels of cytoplasmic RAN proteins.
Data in (B), (C), and (E) indicate mean ± SEM;
data in (D) indicates mean ± SD (*p < 0.05;
**p < 0.01; ***p < 0.001). See also Figure S9.
Neuron
C9ORF72 RNA Toxicity Rescued by Antisenseof the described phenotypes, including glutamate toxicity (Fig-
ures 7F and S9K). Notably, whether the ASO altered a population
of newly synthesized RAN or other RAN products that are not
detected with the present antibodies is not known.
DISCUSSION
Taken together, the current studies provide evidence that RNA
toxicity plays a key role in C9ORF72 ALS based on the molec-
ular, biochemical, and functional studies described here.
Specifically, we have (1) demonstrated that patient fibroblasts
and iPSNs contain intranuclear GGGGCC RNA foci similar to
those found in vivo (DeJesus-Hernandez et al., 2011), (2) iden-
tified numerous proteins that interact with the C9ORF72
GGGGCCexp RNA, (3) confirmed interaction of ADARB2 with
the RNA expansion in vitro and in vivo, (4) described atypical
gene expression in C9ORF72 ALS tissue and cell lines that
match C9ORF72 CNS patient tissue, and (5) determined that
C9ORF72 iPSC neurons are highly susceptible to glutamate
toxicity. Most importantly, by using these various pathological
and physiological readouts in human iPSC neurons, we were
able to identify antisense oligonucleotides that can abrogate
C9ORF72 RNA expansion-dependent pathology, RNA bindingNeuron 80, 415–428,protein aggregation, aberrant gene ex-
pression, and neurotoxicity. Further-
more, ASO that selectively blocked
the hexanucleotide expansion withoutlowering C9ORF72 RNA levels could minimize pathology and
toxicity (Figure 8). Notably, iPSCs derived from ALS patients
appear to accurately recapitulate the pathological and genomic
abnormalities found in the C9ORF72 ALS brain. Modeling this
expansion mutation in animals can be particularly challenging
in part due to the fact that the vast majority of human disease
is caused by very large numbers of G:C-rich repeats that prove
difficult to artificially express. Therefore, human C9ORF72
iPSCs provide an exceptionally valuable tool to investigate
ALS/FTD pathophysiological pathways and therapy develop-
ment and could also be used to validate future in vivo disease
models.
ASOs designed to activate RNase H-mediated C9ORF72 RNA
degradation, or that block the toxic GGGGCCexp RNA, rescued
all of the described pathogenic phenotypes. Interestingly,
ASOs downstream of the repeat were able to rescue some of
the observed toxic phenotypes (e.g., nuclear foci), despite the
fact that our data indicate that RNA far downstream of the repeat
where ASOs D and E target are not sequestered into C9ORF72
intranuclear GGGGCC RNA foci. It is possible that the ASOs
might degrade the RNA very early during transcription and prior
to any splicing events and foci formation as previously described
(Rigo et al., 2012).October 16, 2013 ª2013 Elsevier Inc. 423
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Figure 8. Pathogenesis Resulting from the C9ORF72 Noncoding GGGGCC Expansion in ALS/FTD
Top. Representation of the human C9ORF72 gene, showing hexanucleotide expansion (red) and location of various antisense oligonucleotide (ASO) probes
(B, C, E). Hexanucleotide expansion is located between the noncoding exons 1a and 1b. The expanded RNA is predicted to form a series of G-quartet tertiary
structures. At least three different pathophysiological pathways may results from the mutation: (1) RNA toxicity resulting from excessive binding of various
different RNA binding proteins (green, blue, gray polygons) leading to sequestration of these RBPs, and loss of their activity resulting in anomalous downstream
events; (2) export of the expansion to cytoplasm with repeat-associated translation (RAN) (in the sense or antisense directions) and the formation of excessive
high-molecular-weight cytoplasmic peptides (red), which may be toxic or protective; and (3) loss of C9ORF72 mRNA leading to loss of protein function (not
shown). ASOs may disrupt C9ORF72 RNA toxicity by several pathways. ASO B: an endonuclease-resistant oligonucleotide that is predicted to disrupt the
expansion, interfering with the G-quartet structure and preventing RBP interaction/sequestration. ASO C; a gapmer ASO that binds to the expansion targeting it
RNase H-mediated cleavage and subsequent RNA degradation by nuclear endogenous nucleases, since this ASO targets the repeat it will also disrupt the repeat
sequence structure prior to cleavage and prevent RBP sequestration. ASO E: a gapmer that targets the C9ORF72 RNA coding sequence marking the RNA for
RNase H cleavage, thus resulting in the degradation of wild-type and the expanded C9ORF72 RNA; this will further reduce the already attenuated levels of cellular
C9ORF72 RNA. Notably, ASOs B and C do not reduce cellular C9ORF72 RNA.
Neuron
C9ORF72 RNA Toxicity Rescued by AntisenseThe role of RNA binding proteins in C9ORF72 RNA pathology
as described in this study is supported by recent findings of other
RBPs binding to the GGGGCCexp repeat. Various in vitro pull-
down assays with different sources of cell lysates, such as
human kidney cell lysates and mouse CNS lysates, have identi-
fied commonly known RBPs such as hnRNP (e.g., hnRNPA3)
proteins and Pur a as interactors to the GGGGCCexp repeat
(Xu et al., 2013; Mori et al., 2013a; Almeida et al., 2013). We
tested some of these interactors in our iPSC culture model but
were not able to confirm their nuclear sequestration, similar to
what has been shown using C9ORF72 FTD patient-derived
iPSCs (Almeida et al., 2013). Except for Pur a, none of the previ-
ously described RBPs have been yet shown to have functional
implications for C9ORF72 RNA toxicity; hence, their role in
GGGGCC repeat disease remains unclear. Importantly, tradi-424 Neuron 80, 415–428, October 16, 2013 ª2013 Elsevier Inc.tional pull-down methods to determine protein:RNA interactors
from cell lysates followed by mass spectrometry protein identifi-
cation are limited in that they are biased toward the most abun-
dant proteins of the cell lysates. Proteome arrays, as performed
here, are advantageous for nonbiased interactor screening since
protein abundance will not dictate the identification of candidate
binding partners.
Overall, the current study strongly implicates aberrant RNA
metabolism in the pathogenesis of C9ORF72 disease. More
than a decade ago, aberrant astroglial RNAmetabolism was first
described in ALS (Lin et al., 1998) and some of those patients
were subsequently found to carry the C9ORF72 mutation
(Renton et al., 2011). In order to better understand the mecha-
nism of toxicity associated with the C9ORF72 mutation, we
chose to study in more detail ADARB2 based on its known
Neuron
C9ORF72 RNA Toxicity Rescued by Antisensefunction as a RNA editing regulator. ADAR proteins are a family
of CNS-enriched adenosine deaminases that mediate A-to-I
editing of RNAs such as the (Q/R) site of the GluR2 AMPA recep-
tor (Hideyama et al., 2012). Loss of (Q/R) editing results in Ca2+-
permeable GluR2 receptors that increase neuronal excitation
and cause motor neuron death in a conditional knockout model
(Hideyama et al., 2010). Moreover, improper editing via the
ADAR family has been implicated as a contributor to sporadic
ALS (Hideyama et al., 2012). While the function of ADARB2 in
editing is unclear, it is capable of competitively binding RNAs
to regulate ADAR family editing in vitro (Chen et al., 2000). The
human and iPSC data in the current study suggest that ADARB2
could play a role in human C9ORF72 ALS by interacting with the
C9ORF72 RNA foci. One hypothesis is that the interaction of this
RBP with the GGGGCCexp RNA might result in its loss of func-
tion. Additional studies to investigate the downstream effects
of the loss of ADARB2 on biological processes such as RNA
editing would be important to further characterize the roles of
this protein in CNS cytotoxicity. While we have only thus far
investigated one RBP interactor identified in the present screen
(Table S4), further studies are required to determine whether any
of the other RBPs might interact with the GGGGCCexp RNA
in vivo. Moreover, a GC-rich scrambled RNA sequence was
used, which probably forms a G-quadruplex similar to the
GGGGCC 3 6.5 RNA (Fratta et al., 2012; Reddy et al., 2013),
thereby enriching for structure and sequence-specific protein
interactors. However, the stringency of this analysis might
have inadvertently excluded RBPs whose binding to the
GGGGCC RNA was not apparent since it also showed an affinity
to the GC rich scrambled RNA structure. Finally, it is possible
that multiple RBPs bind to the expansion, leading to either
additive or synergistic effects, implicating various downstream
pathways.
RAN protein has been reported in C9ORF72 tissue and
hypothesized to contribute to disease toxicity. Our studies docu-
ment that C9ORF72 iPSC neurons have at least one RAN protein
and thus recapitulate the pathology seen in human C9ORF72
postmortem brain. However, despite the mitigation of excitotox-
icity, large reductions in RNA foci and RBP aggregation and the
normalization of various genes by the ASO therapy, RAN peptide
can still be detected after ASO treatment. This would suggest
that the detected accumulated cytoplasmic peptide was not a
major contributor to neurotoxicity in our culture model. Although
it is important to note that it is possible that our ASO treatment
could rescue the formation of newly synthesized RAN peptides
and that longer ASO treatment would eventually show a reduc-
tion of RAN products. Furthermore, there could be other RAN
peptides such as, e.g., antisense RAN peptides, contributing
to the observed phenotypes, but that were not detected with
the present antibodies, since our antibody preferentially detects
the poly-(Gly-Pro) RAN product.
While C9ORF72 protein exhibits structural similarity to the
DENN protein family, the function of the C9ORF72 protein
remains unclear (Levine et al., 2013). DENN proteins are GTP-
GDP exchange factors (GEFs) for Rab GTPases, thus implicating
the C9ORF72 protein in vesicular trafficking (Zhang et al., 2012).
C9ORF72 RNA levels are reduced in patients that contain the
expanded allele and a recent study has suggested thatC9ORF72 haploinsufficiency causes neurodegeneration in a
zebrafish model (Ciura et al., 2013). However, a subset of
ASOs utilized in the current study very effectively reduce
C9ORF72 RNA levels by more than 50% (D, E) in the human
iPSNs and rather than being toxic, these ASOs actually abrogate
toxicity associated with the endogenous C9ORF72 mutation.
This strongly suggests that loss of C9ORF72 is not amajor cause
of C9ORF72 ALS pathology and toxicity seen in iPSNs. In sup-
port of this, a recent pathoclinical study revealed that a homozy-
gous mutation, which are generally far more severe for loss of
function disorders, in C9ORF72 mutation individuals had a clin-
ical phenotype similar to heterozygous C9ORF72 mutations,
suggesting that C9ORF72 loss of function was not pathogenic
(Fratta et al., 2013).
EXPERIMENTAL PROCEDURES
Fibroblast Collection, Reprogramming, and iPS Differentiation to
Neurons
Patient fibroblasts were collected at Johns Hopkins Hospital with patient con-
sent (IRB protocol: NA_00021979) or by Dr. Pentti Tienari at the Helsinki
University Central Hospital (Table S1).
Collection of Human Autopsied Tissue
Human autopsied tissue, collected with Institutional Review Board and ethics
approval, used for these data are described in detail in Table S2.
Antisense Oligonucleotide Treatment
Modified 20-methoxyethyl (MOE)/DNA ASOs were generated by Isis Pharma-
ceuticals and the 20 O-methyl RNA (OME)/DNA ASOswere designed by C.J.D.
RNA FISH, Immunofluorescence, and RAN Detection
RNA fluorescent in situ hybridization (FISH) of fibroblasts and iPSNs was per-
formed as previously described (Donnelly et al., 2011) with modification.
Human CNS tissue (see Table S2 for tissue used) was fixed in 4% PFA and
cryoprotected in 30% sucrose. Primary antibody was applied in the following
dilutions: ADARB2, 1:100 (Sigma HPA031333) and TDP-43, 1:500 (Protein-
tech, 10782-2-AP), Pur a, 1:50 (Lifespan), P62, 1:100 (Abcam), hnRNPA1,
1:500 (gift from G. Dreyfuss), hnRNPA1B2, 1:500 (Santa Cruz), and FUS,
1:500 (Sigma). RAN protein products were detected in iPSNs, using the
C9RANT antibody that preferentially detects the poly-(Gly-Pro) RAN product
(Ash et al., 2013). For dot blot analysis of RAN protein products, human tissue
was processed as previously described using urea fractionation (Ash et al.,
2013).
Proteome Array to Identify GGGGCC RNA Interactors
Proteome array was performed as previously described (Jeong et al., 2012;
Rapicavoli et al., 2011) by hybridizing either a 50-Cy5-GGGGCC6.5 HPLC puri-
fied RNA or a 50-Cy5-GGGCGGGGCGGCGCGGGGGCGGGGCGGCGCGG
GGGCGGGG scrambled RNA as a control (IDT DNA).
Nanostring Gene Expression Analysis
RNA was quantified using a probe codeset (Table S3). RNA quantification was
performed with 100–200 ng RNA on an nCounter Analysis System per the
manufacturer’s protocol. RNA counts were normalized using the nCounter
program (Nanostring) and either GAPDH + GUSB for fibroblasts or GAPDH +
GUSB + OAZ1 endogenous controls for iPSN and human tissue.
RNA Isolation and Microarray Analysis
RNA was isolated from cell cultures using the RNeasy Kit with on-column
DNase treatment (QIAGEN). Total RNA was labeled and hybridized to the
human 1.0 ST Exon Array (Affymetrix) at the Johns Hopkins Deep
Sequencing and Microarray Core Facility following the manufacturer’s in-
structions. Microarray raw data were analyzed using the Partek GenomicsNeuron 80, 415–428, October 16, 2013 ª2013 Elsevier Inc. 425
Neuron
C9ORF72 RNA Toxicity Rescued by AntisenseSuite Software (Partek). See the Accession Numbers section below for
microarray data.
Glutamate-Induced Excitotoxicity
For testing C9ORF72 iPSN sensitivity to glutamate-induced excitotoxicity,
healthy control and C9ORF72 iPSNs were treated with various concentrations
of L-glutamate (1, 3, 10, 30, 100 mM) for 2–8 hr. At the appropriate time point,
cells were incubated with 1 mM propidium iodide and 1 mM calcein AM
(Invitrogen) for 30 min to visualize dead and live cells, respectively. For ASO
rescue experiments, iPSNs were treated with ASOs for 72 hr and then treated
with L-glutamate prior to dead/live cell quantification.
Protein Purification and EMSA Binding Analysis
ADARB2 fusion protein was expressed and purified from Rosetta II cells
following gateway expression system (Invitrogen) and GSTrap HP column
purification. Increasing concentrations of purified protein was incubated with
10 nM Cy5-labeled RNA. The fraction of RNA shifted, due to ADARB2 binding,
was densitometrically quantified in ImageJ (NIH).
Microscopy and Image Analysis
Z-stack images were taken on a Zeiss Axioimager with the Apotome tool
or a Zeiss LSM510-meta single-point laser scanning confocal microscope
matched exposure times or laser settings and normalized within their respec-
tive experiment.
Statistical Analysis
Statistical analysis was performed using the Student’s t test or one-way anal-
ysis of variance with the Turkey’s or Dunnet’s post-hoc test and the Prism 6
software (GraphPad Software, Inc.).
Additional details are provided in the Supplemental Experimental
Procedures.
ACCESSION NUMBERS
Microarray data are available in the ArrayExpress database (www.ebi.ac.uk/
arrayexpress) under accession numbers E-MTAB-1925, E-MTAB-1926, and
E-MTAB-1927.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
nine figures, and sixteen tables and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2013.10.015.
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